Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 4411 entries
Sorted by: Best Match Show Resources per page
Serum levels of anti-CCP antibodies, anti-MCV antibodies and RF IgA in the follow-up of patients with rheumatoid arthritis treated with rituximab.

Auto- immunity highlights

Fabris M, De Vita S, Blasone N, Visentini D, Pezzarini E, Pontarini E, Fabro C, Quartuccio L, Mazzolini S, Curcio F, Tonutti E.
PMID: 26000112
Auto Immun Highlights. 2010 Nov 04;1(2):87-94. doi: 10.1007/s13317-010-0013-5. eCollection 2010 Nov.

Rheumatoid arthritis (RA) is characterized by the presence of circulating rheumatoid factor (RF) and anticitrullinated peptide antibodies (ACPA), which are positive in about 70-80% of patients. APCA have a higher specificity and therefore a higher diagnostic power than RF,...

Cite
Fabris M, De Vita S, Blasone N, et al. Serum levels of anti-CCP antibodies, anti-MCV antibodies and RF IgA in the follow-up of patients with rheumatoid arthritis treated with rituximab. Auto Immun Highlights. 2010;1(2):87-94doi: 10.1007/s13317-010-0013-5.
Fabris, M., De Vita, S., Blasone, N., Visentini, D., Pezzarini, E., Pontarini, E., Fabro, C., Quartuccio, L., Mazzolini, S., Curcio, F., & Tonutti, E. (2010). Serum levels of anti-CCP antibodies, anti-MCV antibodies and RF IgA in the follow-up of patients with rheumatoid arthritis treated with rituximab. Auto- immunity highlights, 1(2), 87-94. https://doi.org/10.1007/s13317-010-0013-5
Fabris, Martina, et al. "Serum levels of anti-CCP antibodies, anti-MCV antibodies and RF IgA in the follow-up of patients with rheumatoid arthritis treated with rituximab." Auto- immunity highlights vol. 1,2 (2010): 87-94. doi: https://doi.org/10.1007/s13317-010-0013-5
Fabris M, De Vita S, Blasone N, Visentini D, Pezzarini E, Pontarini E, Fabro C, Quartuccio L, Mazzolini S, Curcio F, Tonutti E. Serum levels of anti-CCP antibodies, anti-MCV antibodies and RF IgA in the follow-up of patients with rheumatoid arthritis treated with rituximab. Auto Immun Highlights. 2010 Nov 04;1(2):87-94. doi: 10.1007/s13317-010-0013-5. eCollection 2010 Nov. PMID: 26000112; PMCID: PMC4389048.
Copy Download .nbib Format: NLM
Rituximab-Induced Acute ST Elevation Myocardial Infarction.

The Ochsner journal

Keswani AN, Williams C, Fuloria J, Polin NM, Jahangir E.
PMID: 26130984
Ochsner J. 2015;15(2):187-90.

BACKGROUND: Rituximab has rarely been associated with acute coronary syndrome (ACS). We report the case of a patient in whom rituximab, a monoclonal antibody used to treat lymphomas of B-cell origin, induced ST elevation myocardial infarction.CASE REPORT: A 46-year-old...

Cite
Keswani AN, Williams C, Fuloria J, et al. Rituximab-Induced Acute ST Elevation Myocardial Infarction. Ochsner J. 2015;15(2):187-90
Keswani, A. N., Williams, C., Fuloria, J., Polin, N. M., & Jahangir, E. (2015). Rituximab-Induced Acute ST Elevation Myocardial Infarction. The Ochsner journal, 15(2), 187-90.
Keswani, Amit N, et al. "Rituximab-Induced Acute ST Elevation Myocardial Infarction." The Ochsner journal vol. 15,2 (2015): 187-90.
Keswani AN, Williams C, Fuloria J, Polin NM, Jahangir E. Rituximab-Induced Acute ST Elevation Myocardial Infarction. Ochsner J. 2015;15(2):187-90. PMID: 26130984; PMCID: PMC4482563.
Copy Download .nbib Format: NLM
Successful treatment of a Caucasian case of multifocal Castleman's disease with TAFRO syndrome with a pathophysiology targeted therapy - a case report.

Experimental hematology & oncology

Tedesco S, Postacchini L, Manfredi L, Goteri G, Luchetti MM, Festa A, Gabrielli A, Pomponio G.
PMID: 25671135
Exp Hematol Oncol. 2015 Jan 14;4(1):3. doi: 10.1186/2162-3619-4-3. eCollection 2015.

BACKGROUND: Castleman-Kojima disease (TAFRO Syndrome) is characterized by Thrombocytopenia, Anasarca, myeloFibrosis, Renal dysfunction, Organomegaly, multiple lymphadenopathy and histopathology pattern of atypical Castleman's disease (CD). Only few cases of this recently identified unique variant of Multicentric CD (MCD) are described...

Cite
Tedesco S, Postacchini L, Manfredi L, et al. Successful treatment of a Caucasian case of multifocal Castleman's disease with TAFRO syndrome with a pathophysiology targeted therapy - a case report. Exp Hematol Oncol. 2015;4(1):3doi: 10.1186/2162-3619-4-3.
Tedesco, S., Postacchini, L., Manfredi, L., Goteri, G., Luchetti, M. M., Festa, A., Gabrielli, A., & Pomponio, G. (2015). Successful treatment of a Caucasian case of multifocal Castleman's disease with TAFRO syndrome with a pathophysiology targeted therapy - a case report. Experimental hematology & oncology, 4(1), 3. https://doi.org/10.1186/2162-3619-4-3
Tedesco, Silvia, et al. "Successful treatment of a Caucasian case of multifocal Castleman's disease with TAFRO syndrome with a pathophysiology targeted therapy - a case report." Experimental hematology & oncology vol. 4,1 (2015): 3. doi: https://doi.org/10.1186/2162-3619-4-3
Tedesco S, Postacchini L, Manfredi L, Goteri G, Luchetti MM, Festa A, Gabrielli A, Pomponio G. Successful treatment of a Caucasian case of multifocal Castleman's disease with TAFRO syndrome with a pathophysiology targeted therapy - a case report. Exp Hematol Oncol. 2015 Jan 14;4(1):3. doi: 10.1186/2162-3619-4-3. eCollection 2015. PMID: 25671135; PMCID: PMC4322808.
Copy Download .nbib Format: NLM
Desensitization Strategies Pre- and Post-Cardiac Transplantation.

Current treatment options in cardiovascular medicine

Cole RM, Kobashigawa JA.
PMID: 26781656
Curr Treat Options Cardiovasc Med. 2016 Feb;18(2):8. doi: 10.1007/s11936-015-0431-9.

OPINION STATEMENT: Panel reactive antibody (PRA) testing has become standard in the evaluation of patients prior to cardiac transplant. Sensitizing events such as blood transfusions, which result in the accumulation of pre-transplant antibodies, should be avoided as clinically feasible....

Cite
Cole RM, Kobashigawa JA. Desensitization Strategies Pre- and Post-Cardiac Transplantation. Curr Treat Options Cardiovasc Med. 2016;18(2):8doi: 10.1007/s11936-015-0431-9.
Cole, R. M., & Kobashigawa, J. A. (2016). Desensitization Strategies Pre- and Post-Cardiac Transplantation. Current treatment options in cardiovascular medicine, 18(2), 8. https://doi.org/10.1007/s11936-015-0431-9
Cole, Robert M, and Kobashigawa, Jon A. "Desensitization Strategies Pre- and Post-Cardiac Transplantation." Current treatment options in cardiovascular medicine vol. 18,2 (2016): 8. doi: https://doi.org/10.1007/s11936-015-0431-9
Cole RM, Kobashigawa JA. Desensitization Strategies Pre- and Post-Cardiac Transplantation. Curr Treat Options Cardiovasc Med. 2016 Feb;18(2):8. doi: 10.1007/s11936-015-0431-9. PMID: 26781656.
Copy Download .nbib Format: NLM
Effects of rituximab on lymphocytes in multiple sclerosis and neuromyelitis optica.

Multiple sclerosis and related disorders

Graves J, Vinayagasundaram U, Mowry EM, Matthews IR, Marino JA, Cheng J, Waubant E.
PMID: 25878012
Mult Scler Relat Disord. 2014 Mar;3(2):244-52. doi: 10.1016/j.msard.2013.10.003. Epub 2013 Oct 25.

OBJECTIVE: To investigate the effect of rituximab, a B-cell targeted therapy that is used in the treatment of multiple sclerosis (MS) and neuromyelitis optica (NMO), on other immune cells such as CD4+ and CD8+ T-cells in patients with MS...

Cite
Graves J, Vinayagasundaram U, Mowry EM, et al. Effects of rituximab on lymphocytes in multiple sclerosis and neuromyelitis optica. Mult Scler Relat Disord. 2013;3(2):244-52doi: 10.1016/j.msard.2013.10.003.
Graves, J., Vinayagasundaram, U., Mowry, E. M., Matthews, I. R., Marino, J. A., Cheng, J., & Waubant, E. (2014). Effects of rituximab on lymphocytes in multiple sclerosis and neuromyelitis optica. Multiple sclerosis and related disorders, 3(2), 244-52. https://doi.org/10.1016/j.msard.2013.10.003
Graves, Jennifer, et al. "Effects of rituximab on lymphocytes in multiple sclerosis and neuromyelitis optica." Multiple sclerosis and related disorders vol. 3,2 (2014): 244-52. doi: https://doi.org/10.1016/j.msard.2013.10.003
Graves J, Vinayagasundaram U, Mowry EM, Matthews IR, Marino JA, Cheng J, Waubant E. Effects of rituximab on lymphocytes in multiple sclerosis and neuromyelitis optica. Mult Scler Relat Disord. 2014 Mar;3(2):244-52. doi: 10.1016/j.msard.2013.10.003. Epub 2013 Oct 25. PMID: 25878012.
Copy Download .nbib Format: NLM
Primary Diffuse Large B-cell Lymphoma Arising in the Tongue Accompanied by Ataxia-telangiectasia: A Case Report.

Journal of clinical and diagnostic research : JCDR

Tomioka H, Kaneoya A, Mochizuki Y, Harada H.
PMID: 26266230
J Clin Diagn Res. 2015 Jun;9(6):ZD25-7. doi: 10.7860/JCDR/2015/12121.6107. Epub 2015 Jun 01.

Ataxia-telangiectasia (AT) is a rare autosomal recessive disorder that is characterized by progressive cerebellar ataxia, telangiectasia, immunodeficiency, and a predisposition to leukemia/lymphoma. Here we report a rare case of lymphoma of the tongue accompanied by AT. Tumour extirpation was...

Cite
Tomioka H, Kaneoya A, Mochizuki Y, et al. Primary Diffuse Large B-cell Lymphoma Arising in the Tongue Accompanied by Ataxia-telangiectasia: A Case Report. J Clin Diagn Res. 2015;9(6):ZD25-7doi: 10.7860/JCDR/2015/12121.6107.
Tomioka, H., Kaneoya, A., Mochizuki, Y., & Harada, H. (2015). Primary Diffuse Large B-cell Lymphoma Arising in the Tongue Accompanied by Ataxia-telangiectasia: A Case Report. Journal of clinical and diagnostic research : JCDR, 9(6), ZD25-7. https://doi.org/10.7860/JCDR/2015/12121.6107
Tomioka, Hirofumi, et al. "Primary Diffuse Large B-cell Lymphoma Arising in the Tongue Accompanied by Ataxia-telangiectasia: A Case Report." Journal of clinical and diagnostic research : JCDR vol. 9,6 (2015): ZD25-7. doi: https://doi.org/10.7860/JCDR/2015/12121.6107
Tomioka H, Kaneoya A, Mochizuki Y, Harada H. Primary Diffuse Large B-cell Lymphoma Arising in the Tongue Accompanied by Ataxia-telangiectasia: A Case Report. J Clin Diagn Res. 2015 Jun;9(6):ZD25-7. doi: 10.7860/JCDR/2015/12121.6107. Epub 2015 Jun 01. PMID: 26266230; PMCID: PMC4525621.
Copy Download .nbib Format: NLM
Pulmonary Mucormycosis in a Patient with Systemic Lupus Erythematosus: A Diagnostic and Treatment Challenge.

Case reports in infectious diseases

Hung HC, Shen GY, Chen SC, Yeo KJ, Tsao SM, Lee MC, Lee YT.
PMID: 26185693
Case Rep Infect Dis. 2015;2015:478789. doi: 10.1155/2015/478789. Epub 2015 Jun 22.

Pulmonary mucormycosis is commonly encountered in patients with diabetic ketoacidosis, hematologic malignancies, neutropenia, organ or hematopoietic stem cell transplantation, and malignancy, but it rarely occurs in high-risk patients with systemic lupus erythematosus (SLE). We present the case of a...

Cite
Hung HC, Shen GY, Chen SC, et al. Pulmonary Mucormycosis in a Patient with Systemic Lupus Erythematosus: A Diagnostic and Treatment Challenge. Case Rep Infect Dis. 2015;2015:478789doi: 10.1155/2015/478789.
Hung, H. C., Shen, G. Y., Chen, S. C., Yeo, K. J., Tsao, S. M., Lee, M. C., & Lee, Y. T. (2015). Pulmonary Mucormycosis in a Patient with Systemic Lupus Erythematosus: A Diagnostic and Treatment Challenge. Case reports in infectious diseases, 2015478789. https://doi.org/10.1155/2015/478789
Hung, Hung-Chang, et al. "Pulmonary Mucormycosis in a Patient with Systemic Lupus Erythematosus: A Diagnostic and Treatment Challenge." Case reports in infectious diseases vol. 2015 (2015): 478789. doi: https://doi.org/10.1155/2015/478789
Hung HC, Shen GY, Chen SC, Yeo KJ, Tsao SM, Lee MC, Lee YT. Pulmonary Mucormycosis in a Patient with Systemic Lupus Erythematosus: A Diagnostic and Treatment Challenge. Case Rep Infect Dis. 2015;2015:478789. doi: 10.1155/2015/478789. Epub 2015 Jun 22. PMID: 26185693; PMCID: PMC4491550.
Copy Download .nbib Format: NLM
Disease exacerbation after rituximab induction in neuromyelitis optica.

Neurology(R) neuroimmunology & neuroinflammation

Perumal JS, Kister I, Howard J, Herbert J.
PMID: 25738163
Neurol Neuroimmunol Neuroinflamm. 2015 Feb 05;2(1):e61. doi: 10.1212/NXI.0000000000000061. eCollection 2015 Feb.

No abstract available.

Cite
Perumal JS, Kister I, Howard J, et al. Disease exacerbation after rituximab induction in neuromyelitis optica. Neurol Neuroimmunol Neuroinflamm. 2015;2(1):e61doi: 10.1212/NXI.0000000000000061.
Perumal, J. S., Kister, I., Howard, J., & Herbert, J. (2015). Disease exacerbation after rituximab induction in neuromyelitis optica. Neurology(R) neuroimmunology & neuroinflammation, 2(1), e61. https://doi.org/10.1212/NXI.0000000000000061
Perumal, Jai S, et al. "Disease exacerbation after rituximab induction in neuromyelitis optica." Neurology(R) neuroimmunology & neuroinflammation vol. 2,1 (2015): e61. doi: https://doi.org/10.1212/NXI.0000000000000061
Perumal JS, Kister I, Howard J, Herbert J. Disease exacerbation after rituximab induction in neuromyelitis optica. Neurol Neuroimmunol Neuroinflamm. 2015 Feb 05;2(1):e61. doi: 10.1212/NXI.0000000000000061. eCollection 2015 Feb. PMID: 25738163; PMCID: PMC4335814.
Copy Download .nbib Format: NLM
Current approaches and advance in mantle cell lymphoma treatment.

Stem cell investigation

Liu Y, Zhang X, Zhong JF.
PMID: 27358886
Stem Cell Investig. 2015 Sep 29;2:18. doi: 10.3978/j.issn.2306-9759.2015.09.02. eCollection 2015.

Mantle cell lymphoma (MCL) is a set of heterogeneous non-Hodgkin lymphoma characterized by involvement of lymph nodes, spleen, bone marrow and blood. Under conventional treatment, survival time is 4 to 5 years with short remission period and there is...

Cite
Liu Y, Zhang X, Zhong JF. Current approaches and advance in mantle cell lymphoma treatment. Stem Cell Investig. 2015;2:18doi: 10.3978/j.issn.2306-9759.2015.09.02.
Liu, Y., Zhang, X., & Zhong, J. F. (2015). Current approaches and advance in mantle cell lymphoma treatment. Stem cell investigation, 218. https://doi.org/10.3978/j.issn.2306-9759.2015.09.02
Liu, Yao, et al. "Current approaches and advance in mantle cell lymphoma treatment." Stem cell investigation vol. 2 (2015): 18. doi: https://doi.org/10.3978/j.issn.2306-9759.2015.09.02
Liu Y, Zhang X, Zhong JF. Current approaches and advance in mantle cell lymphoma treatment. Stem Cell Investig. 2015 Sep 29;2:18. doi: 10.3978/j.issn.2306-9759.2015.09.02. eCollection 2015. PMID: 27358886; PMCID: PMC4923656.
Copy Download .nbib Format: NLM
Profile of venetoclax and its potential in the context of treatment of relapsed or refractory chronic lymphocytic leukemia.

OncoTargets and therapy

Huber H, Edenhofer S, Estenfelder S, Stilgenbauer S.
PMID: 28223822
Onco Targets Ther. 2017 Feb 07;10:645-656. doi: 10.2147/OTT.S102646. eCollection 2017.

Over the last few years, dramatic changes have occurred in the treatment of chronic lymphocytic leukemia (CLL). The current standard for young and fit patients with CLL remains chemoimmunotherapy, namely the fludarabine, cyclophosphamide, and rituximab (FCR) regimen. However, novel...

Cite
Huber H, Edenhofer S, Estenfelder S, et al. Profile of venetoclax and its potential in the context of treatment of relapsed or refractory chronic lymphocytic leukemia. Onco Targets Ther. 2017;10:645-656doi: 10.2147/OTT.S102646.
Huber, H., Edenhofer, S., Estenfelder, S., & Stilgenbauer, S. (2017). Profile of venetoclax and its potential in the context of treatment of relapsed or refractory chronic lymphocytic leukemia. OncoTargets and therapy, 10645-656. https://doi.org/10.2147/OTT.S102646
Huber, Henriette, et al. "Profile of venetoclax and its potential in the context of treatment of relapsed or refractory chronic lymphocytic leukemia." OncoTargets and therapy vol. 10 (2017): 645-656. doi: https://doi.org/10.2147/OTT.S102646
Huber H, Edenhofer S, Estenfelder S, Stilgenbauer S. Profile of venetoclax and its potential in the context of treatment of relapsed or refractory chronic lymphocytic leukemia. Onco Targets Ther. 2017 Feb 07;10:645-656. doi: 10.2147/OTT.S102646. eCollection 2017. PMID: 28223822; PMCID: PMC5308588.
Copy Download .nbib Format: NLM
Long-term survival in a patient with progressive multifocal leukoencephalopathy after therapy with rituximab, fludarabine and cyclophosphamide for chronic lymphocytic leukemia.

Experimental hematology & oncology

Garrote H, de la Fuente A, Oña R, Rodríguez I, Echevarría JE, Sepúlveda JM, García JF.
PMID: 25767742
Exp Hematol Oncol. 2015 Mar 01;4:8. doi: 10.1186/s40164-015-0003-4. eCollection 2015.

A 50-year-old male with chronic lymphocytic leukemia (CLL) was treated with fludarabine, cyclophosphamide and rituximab, which produced a complete remission. Eight months after the last dose of rituximab he had visual disturbance, diminished muscular strength in the right arm...

Cite
Garrote H, de la Fuente A, Oña R, et al. Long-term survival in a patient with progressive multifocal leukoencephalopathy after therapy with rituximab, fludarabine and cyclophosphamide for chronic lymphocytic leukemia. Exp Hematol Oncol. 2015;4:8doi: 10.1186/s40164-015-0003-4.
Garrote, H., de la Fuente, A., Oña, R., Rodríguez, I., Echevarría, J. E., Sepúlveda, J. M., & García, J. F. (2015). Long-term survival in a patient with progressive multifocal leukoencephalopathy after therapy with rituximab, fludarabine and cyclophosphamide for chronic lymphocytic leukemia. Experimental hematology & oncology, 48. https://doi.org/10.1186/s40164-015-0003-4
Garrote, Heidys, et al. "Long-term survival in a patient with progressive multifocal leukoencephalopathy after therapy with rituximab, fludarabine and cyclophosphamide for chronic lymphocytic leukemia." Experimental hematology & oncology vol. 4 (2015): 8. doi: https://doi.org/10.1186/s40164-015-0003-4
Garrote H, de la Fuente A, Oña R, Rodríguez I, Echevarría JE, Sepúlveda JM, García JF. Long-term survival in a patient with progressive multifocal leukoencephalopathy after therapy with rituximab, fludarabine and cyclophosphamide for chronic lymphocytic leukemia. Exp Hematol Oncol. 2015 Mar 01;4:8. doi: 10.1186/s40164-015-0003-4. eCollection 2015. PMID: 25767742; PMCID: PMC4357158.
Copy Download .nbib Format: NLM
Acquired factor VIII deficiency: two case reports and a review of literature.

Experimental hematology & oncology

Mo L, Bao GC.
PMID: 28352491
Exp Hematol Oncol. 2017 Mar 24;6:8. doi: 10.1186/s40164-017-0068-3. eCollection 2017.

BACKGROUND: Acquired factor VIII (FVIII) deficiency, or acquired hemophilia A (AHA), is a rare autoimmune disorder involving antibody-mediated depletion of coagulation FVIII, leading to severe, life-threatening bleeding. The condition is often associated with other autoimmune disorders, and its treatment...

Cite
Mo L, Bao GC. Acquired factor VIII deficiency: two case reports and a review of literature. Exp Hematol Oncol. 2017;6:8doi: 10.1186/s40164-017-0068-3.
Mo, L., & Bao, G. C. (2017). Acquired factor VIII deficiency: two case reports and a review of literature. Experimental hematology & oncology, 68. https://doi.org/10.1186/s40164-017-0068-3
Mo, Lan, and Bao, George C. "Acquired factor VIII deficiency: two case reports and a review of literature." Experimental hematology & oncology vol. 6 (2017): 8. doi: https://doi.org/10.1186/s40164-017-0068-3
Mo L, Bao GC. Acquired factor VIII deficiency: two case reports and a review of literature. Exp Hematol Oncol. 2017 Mar 24;6:8. doi: 10.1186/s40164-017-0068-3. eCollection 2017. PMID: 28352491; PMCID: PMC5366150.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 4411 entries